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ever, the mechanism underlying ATRA-induced RIG-G induction is not completely understood. Here,
we demonstrate that ATRA up-regulates the expression of PU.1, which in turn directly binds to the
promoter and increases the expression of RIG-G gene. Luciferase reporter assay and electrophoretic
mobility shift assay reveal that PU.1 preferentially binds to one of the two putative binding sites on
the RIG-G promoter. Moreover, silencing of PU.1 by shRNA markedly inhibited ATRA- but not IFNa-
induced expression of RIG-G. These data provide new insight into the mechanism of ATRA-induced
RIG-G expression.
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Hematopoiesis is tightly regulated by a set of transcription
factors, including PU.1/spi-1, CCAAT/enhancer binding proteins
(C/EBPs) and runt-related transcription factor 1 (RUNX1), which
governs the expression of the downstream genes to thus regulates
their functions at different cellular stages [1]. PU.1 expression is
mainly restricted to hematopoietic cell lineages and is proved to
be indispensable for myeloid and lymphoid cell development [2].
Deregulation of PU.1 is involved in various hematopoietic malig-
nancies. Increased expression of PU.1 in erythroid precursors in-
duces erythroleukemia in transgenic mice [3], whereas reduction
of PU.1 expression leads to acute myeloid leukemias (AML) [4].
In acute promyelocytic leukemia (APL) blasts, expression of PU.1
is suppressed by PML-RARa (promyelocytic leukemia-retinoic acid
receptor a) fusion protein and can be restored by ATRA (all-trans
retinoic acid) treatment [5]. The restoration of PU.1 expression is
sufﬁcient to trigger neutrophil differentiation while the knock-
down of PU.1 gene impairs ATRA-induced differentiation [5], indi-chemical Societies. Published by E
g-Qing South Rd., Shanghai
liwu@163.com (Y.-L. Wu).cating that PU.1 and its target genes play critical roles in ATRA-
induced differentiation.
The retinoic acid-induced gene G (RIG-G), belonging to the
Interferon-inducible (IFI) gene family, was originally identiﬁed in
APL-derived NB4 cells treated by ATRA [6]. In addition to ATRA,
the expression of RIG-G can also be rapidly induced by interferon
a (IFNa) in hematopoietic cell lines as well as in various types of
solid carcinoma cells [6,7]. Subsequently, RIG-G induces growth
arrest and facilitates cell differentiation by up-regulating P27 and
P21 in leukemic U937 cells [8].
Tong et al. demonstrated that IFNa autocrine contributed to
ATRA-induced RIG-G expression through an interferon regulatory
factor 9 (IRF-9)/signal transducer and activator of transcription 2
(STAT2)- and interferon regulatory factor 1 (IRF-1)-dependent
pathway [9]. In the present study, we revealed a novel pathway
involved in ATRA-induced expression of RIG-G in leukemic cells,
that is, PU.1 could directly bind to the RIG-G promoter and activate
the expression of RIG-G in leukemia cells.
2. Materials and methods
2.1. Cell culture and treatment
Leukemia cell lines U937, U937NC, U937shPU.1, U937Tempty and
U937TFLAG-PU.1 (generated as previous reported [10]) were culturedlsevier B.V. All rights reserved.
Fig. 1. PU.1 upregulates RIG-G in U937T cells (A and B) U937 cells were treated with ATRA at 1 lM (A) or IFNa at 3000 U/ml (B) for indicated times. Cells were collected and
subjected to Western blot with indicated antibodies. (C and D) U937empty and U937FLAG-PU.1 cells were washed twice with PBS and seeded in the medium without tetracycline.
Cells were collected each day for detection of proteins (C) and mRNAs (D) as indicated. b-actin was used as internal control both in Western blot and real-time PCR
experiments. The error bar in real-time PCR experiment represented S.D. of three independent samples and each experiment was repeated for three times. The number on the
bottom of the tested protein indicates signal intensity of the protein against b-actin (A, B and C). Symbol  represents P < 0.01.
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mented with 10% fetal bovine serum (FBS, Gibco BRL, Gaithersburg,
MD). Tetracycline at 1 lg/ml was included for the maintenance of
U937Tempty and U937TFLAG-PU.1 cells. Cells were treated with ATRA
(Sigma–Aldrich) at 1 lM and IFNa (Roche Applied Science,
Indianapolis, IN) at 3000 U/ml.
2.2. Quantitative real-time PCR
Quantitative real-time PCR analysis was performed as
previously described [11]. The following speciﬁc primers were
used: 50-GAAGGACAGCATCTGGTGGGT-30 (forward) and 50-GCCG-
TCTTGCCGTAGTTGC-30 (reverse) for PU.1, 50-AACTACGCCTGGGTC-
TACTATCACT-30 (forward) and 50-ACACCTTCGCCCTTTCATTTC-30
(reverse) for RIG-G, and 50-CATCCTCACCCTGAAGTACCC-30 (forward)
and 50-AGCCTGGATAGCAACGTACATG-30 (reverse) for b-actin as
control.
2.3. Luciferase assay
The luciferase reporter pXP2 carrying the sequence of310 bp to
+51 bp of 50-ﬂanking region of RIG-G gene was a kind gift from Jian-
Hua Tong (Ruijin hospital, Shanghai, China). The site-directedmuta-
genesis kit (Stratagene, La Jolla, CA)wasused for thepointmutations
of thePU.1binding site (TTCCTC toTCTCTC) of the reporter luciferase
plasmids following the manufacturer’s instructions. For the lucifer-
ase assay, 293T cells were seeded in a 12-well plate (Becton Dickin-
son, Franklin lakes, NJ), and were cotransfected with pCMV4-PU.1and pRLSV40-Renilla. Total amounts of plasmids in each transfec-
tion were equalized by its empty vector. After 24 h, cells were lyzed
and analyzed by the Dual-Luciferase Assay system according to the
manufacturer’s instructions (Promega, Madison, WI).
2.4. Chromatin immunoprecipitation (ChIP)
ATRA or IFNa treated U937 cells were subjected to ChIP assay as
described [11] previously using the speciﬁc anti-human PU.1 anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA). PCR for the PU.1
binding sites in the promoter was performed with speciﬁc primers:
50-GGTCTCAAGCCGTTAGGTTTC-30 (forward) and 50-TGACCAGGCT-
GATTTGTTCTTC-30 (reverse).
2.5. Electrophoretic mobility shift assay (EMSA)
293T cells were transfected with PU.1 plasmid for 24 h and nu-
clear extracts were prepared using the Nuclear and Cytoplasmic
Extraction Kit (Pierce Biotech, Rockford, IL). The wild type oligonu-
cleotides (50-CGTTAGGTTTCATTTTCCTCCTCCCAACGATTTT-30, 50-TT
TCACTTTCCAGTTTCCTCTTCCTTCCCCTAAA-30) and mutated oligo-
nucleotides (50-CGTTAGGTTTCATTTCTCTCCTCCCAACGATTTT-30, 50-
TTTCACTTTCCAGTTCTCTCTTCCTTCCCCTAAA-30) were biotin-labeled
using the Biotin 30-End DNA Labeling Kit (Pierce Biotech) and an-
nealed with their complementary strands. Oligonucleotides with
nuclear factor kappa B (NF-jB) binding site were used as non-re-
lated competitor (50-AGTTGAGGGGACTTTCCCAGGC-30). EMSA as-
say was performed as described previously [12].
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Western blot was performed as described previously [11] using
the polyclonal antibodies against PU.1, FLAG (Santa Cruz Biotech-
nology), C/EBPa (Abcam, Cambridge, MA), RUNX1 (Cell Signaling,
Beverly, MA) and RIG-G (from Jian-Hua Tong, Ruijin hospital,
Shanghai, China). b-actin (Merck, Darmstadt, Germany) or Lamin
B (Santa Cruz Biotechnology) was used as internal controls. The
signal intensity of the bands was quantiﬁed using Quantity One
(Bio-Rad, version 4.4.0).2.7. Statistical analysis
Student’s t-test was used to evaluate the difference between
two different groups. A P value of less than 0.05 was considered
statistically signiﬁcant.Fig. 2. PU.1 binds to and transactivates the promoter of RIG-G gene. (A) Genomic
sequence of 50-ﬂanking region of RIG-G gene. Two putative PU.1 binding sites were
boxed with solid line, two previously reported ISREs were boxed with dashed line,
TATA box was lined and the transcription start site +1 was indicated with an arrow.
(B) Untreated U937 cells (control), U937 cells treated with ATRA at 1 lM for 48 h or
IFNa at 3000 U/ml for 4 h were subjected to ChIP assay as described in Section 2. (C)
Luciferase activities described in Section 2 and the expression of PU.1 were
determined with Lamin B as internal control after 24 h. The error bar represented
S.D. of three independent samples and each experiment was repeated for three
times. Symbol  represents P < 0.01 compared with empty vector transfected group.3. Results
3.1. PU.1 upregulates RIG-G in U937T cells
To investigate the possible relationship between the hemato-
poiesis-related transcription factors and the expression of RIG-G,
the leukemic cell line U937 was employed, taking advantage of
the convenience of its gene manipulation. As shown in Fig. 1A, a
rapid increase of PU.1 protein but not C/EBPa or RUNX1 was ob-
served after ATRA treatment, which was followed by upregulation
of RIG-G protein, indicating that PU.1 is a potential regulator of
RIG-G. No substantial change of any of the three transcription fac-
tors was observed during the induction of RIG-G by IFNa (Fig. 1B).
To examine whether PU.1 could regulate the expression of RIG-G,
U937TPU.1, in which the FLAG-tagged PU.1 could be induced by
tetracycline withdrawal, was utilized. As expected, it was ob-
served that tetracycline withdrawal led to the upregulation of
PU.1 from day 2 and the maintenance of the high protein level
in the following 5 days. On the contrary, expression of PU.1 in
the empty cells stayed unchanged (Fig. 1C). Interestingly, the level
of RIG-G protein was also observed to increase from day 2 in
synchronization with that of PU.1. Real-time PCR experiment
demonstrated that induced expression of PU.1 transcriptionally
upregulated RIG-G (Fig. 1D), suggesting that RIG-G might be a
downstream target of PU.1.3.2. PU.1 binds to and transactivates the promoter of RIG-G gene
Based on the observation that PU.1 could elevate mRNA of RIG-
G gene, we deduced that PU.1 could exert its effect by directly
binding to the promoter of RIG-G. A bioinformatics analysis of
the 2 kb region upstream of the transcriptional start site of RIG-
G revealed two well conserved PU.1 binding sites (Supplementary
Fig. S1) that are upstream of TATA box and near the previous
reported ISREs [8] (Fig. 2A). To elucidate whether PU.1 could
directly bind to the promoter of RIG-G in vivo, ChIP assay was
performed using PU.1 speciﬁc antibody in ATRA- or IFNa-treated
U937 cells. As shown in Fig. 2B, PU.1 antibody but not IgG was
able to precipitate the sequence containing two PU.1 binding
sites. Furthermore, both treatment with ATRA for 48 h and IFNa
for 4 h enhanced more binding of PU.1 to the promoter region
than the control cells (Fig. 2B, Supplementary Fig. S2) indicating
that PU.1 binding to the promoter of RIG-G gene was stimulated
by the presence of ATRA or IFNa. The promoter of RIG-G was acti-
vated by PU.1 plasmids in a dose-dependent manner (Fig. 2C),
suggesting that PU.1 is a direct transcription regulator of RIG-G
gene.3.3. Site 2 not 1 is responsible for the activity of PU.1 in the promoter of
RIG-G gene
To elucidate which site was responsible for the activity of PU.1
in the promoter of RIG-G gene, the luciferase reporter plasmids
pXP2 was mutated as illustrated in Fig. 3A. Dual luciferase repor-
ter experiment showed that site 2 mutation suppressed the acti-
vation of the promoter by PU.1, whereas mutation of site 1 had no
effect (Fig. 3B). Accordingly, no further suppression was observed
in the double mutant, indicating that site 2 was the only site
responsible for the promoter activation by PU.1 (Fig. 3B). To fur-
ther conﬁrm the binding site for PU.1, EMSA experiment was per-
formed with wild-type and mutated probes. As shown in Fig. 3C,
the probe with wild-type site 2 sequence was shifted by PU.1-
containing nuclear extract, and the shifting effect was competed
off by cold wild-type probe, unaffected by non-related probe,
and supershifted by PU.1 antibody. In addition, the probes with
mutated site 2, or wild-type or mutated site 1 sequences did
not show the speciﬁc shifted band in the presence of PU.1. These
observations unambiguously proved that site 2 but not site 1 on
the promoter of RIG-G gene serves as the speciﬁc PU.1 interaction
site.
Fig. 3. Site 2 not 1 is responsible for the activity of PU.1 on the promoter of RIG-G gene. (A) Illustration of PU.1 binding sites mutants. (B) 293T cells were transfected with
250 ng plasmids of PU.1 together with indicated mutants of RIG-G promoter-luciferase construct pXP2 and Renilla. Luciferase activities and the expression of PU.1 with Lamin
B as internal control were determined after 24 h. The error bar represented S.D. of three independent samples and each experiment was repeated for three times. (C) EMSA
experiment as described in Section 2 was used to demonstrate the actual PU.1 binding site in vitro.
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U937 cells
To further demonstrate the role of PU.1 in the regulation of
RIG-G, U937shPU.1 cells were used, in which PU.1 expression
was stably knocked down. It was observed the protein
(Fig. 4A) and mRNA (Fig. 4B) of RIG-G increased at day 2 and
further increased at day 3 in the ATRA-treated U937NC cells.
However, in ATRA treated U937shPU.1 cells, no signiﬁcant increase
of RIG-G was observed (Fig. 4A and B), indicating that PU.1
played a key role in the ATRA-induced expression of RIG-G. In
Fig. 4C and D, IFNa treatment could induce the expression of
RIG-G without changing the PU.1 expression in U937NC and
U937shPU.1 cells. However, knock down of PU.1 did signiﬁcantly
inhibit IFNa induced RIG-G expression at protein and mRNA le-
vel at 4 h, while a mild suppression was observed at 8 h, indicat-
ing that PU.1 is involved in the initial stage of IFNa-induced
expression of RIG-G.4. Discussion
RIG-G, potently inhibiting cell growth through upregulation of
p21 and p27, was previously reported to be upregulated by ATRA
and IFNa [8,9]. Along this line, Tong et al. [9] proposed that ATRA
induced the upregulation of RIG-G partially through an IFNa auto-
crine pathway. In this work, we demonstrated that ATRA upregu-
lates the expression of PU.1, which in turn directly binds to the
promoter of RIG-G gene and increases its expression.
The role of PU.1 and C/EBPa in transactivating RIG-G promoter
in U3A cells, which is deﬁcient in the expression of signal trans-
ducer and activator of transcription 1 (STAT1), was previously eval-
uated by Tong et al. using a luciferase reporter assay [9]. However,
no signiﬁcant change of RIG-G level was observed after PU.1 trans-
fection while C/EBPa even showed a repressive effect [9]. This
discrepancy could be explained by the fact that the regulation of
RIG-G is cell type speciﬁc. As the expression of PU.1 is restricted
to myeloid and lymphoid lineages [13], the leukemia cell line is a
Fig. 4. Knockdown of PU.1 suppresses ATRA-induced expression of RIG-G in U937 cells U937NC and U937shPU.1 cells were treated with ATRA at 1 lM (A and B) or IFNa at
3000 U/ml (C and D) for indicated time. Cells were collected at each time point to detect of protein (A and C) and mRNA (B and D) as indicated. b-actin was used as internal
control both inWestern blot and real-time PCR experiments. The number on the bottom of the tested protein indicates signal intensity of the protein against b-actin (A and C).
The error bar in real-time PCR experiment represented S.D. of three independent samples and each experiment was repeated for three times. The symbol  represents P < 0.01,
# represents P < 0.05.
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gene. Thus, it was found that inducible expression of PU.1 in
U937 cells concurrently upregulated RIG-G while knockdown of
PU.1 reduced ATRA-induced expression of RIG-G and differentia-
tion (Supplementary Fig. S3), indicating PU.1 played an important
role in the ATRA-induced expression of RIG-G. As a further evi-
dence, PU.1 or RIG-G was not upregulated by ATRA treatment in
ATRA-resistant NB4-R1 cells [5,9].
It is interesting to note that both ATRA and IFNa could increase
the binding of PU.1 to the promoter of RIG-G, while only ATRA
could increase the protein level of PU.1. In contrast to treatment
of ATRA, IFNa induced recruitment of PU.1 to the promoter of
RIG-G gene instead of increase the protein of PU.1. PU.1 could also
function as a partner of other transcription factors activated by
IFNa, such as STATs [14,15] or interferon regulatory factors
[16,17], to regulate the induction of RIG-G. These factors may also
contribute to ATRA induced upregulation of RIG-G [18–20]. Thus,
PU.1 knockdown abrogated ATRA-induced but only delayed IFNa-
induced expression of RIG-G. These data suggested that PU.1, as a
newly discovered player, contributed to both ATRA- and IFNa-
induced expression of RIG-G, particularly exerting stronger effect
on the former. Moreover, combined treatment of ATRA and IFNa
resulted in a synergistic effect at 48 h (Supplementary Fig. S4).
In summary, we demonstrated that PU.1 directly binds to and
transactivates one of the two binding sites in RIG-G promoter,
which provided new insight for the understanding of ATRA-
induced RIG-G expression.
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